|Author (Corporate)||European Commission: DG Migration and Home Affairs|
|Series Details||COM (2022) 18|
Legislative initiative tabled by the European Commission on 12 January 2022, revising the mandate of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and transforming it into the European Union Drugs Agency.
Regulation (EC) No 1920/2006 revised the framework establishing the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Following the fourth evaluation of the Centre in line with the requirements of the Regulation, the European Commission concluded that while it worked well, further improvements were possible in several areas. The finding was further substantiated during contacts with the EMCDDA and its stakeholders. It became clear that Regulation (EC) No 1920/2006 did not reflect an evolving reality of the drug phenomenon and was out of step with the tasks the Centre needed to perform to address the related challenges.
The EU Drugs Strategy 2021-2025 and the EU Drugs Action Plan 2021-2025 call for a revision of the mandate of the EMCDDA. The European Commission tabled a draft law on 12 January 2022 delivering on that commitment. The proposed changes aim to ensure that the new European Union Drugs Agency can play a more important role in identifying and addressing challenges related to illicit drugs in the European Union (EU). This includes issuing alerts when dangerous substances are knowingly sold for illicit use, monitoring the addictive use of substances taken together with illicit drugs, and developing EU-level prevention campaigns. The role of the Agency in the international arena is also clarified.
|Subject Categories||Justice and Home Affairs|
|Keywords||EU Agencies, European Monitoring Centre for Drugs and Drug Addiction [EMCDDA]
|International Organisations||European Union [EU]|